Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Current Quarter	$-0.1	Next Quarter	$-0.11
Current Year	$-0.62	Next Year	$-0.34
QoQ Growth	-10.0%	YoY Growth	+45.2%
3Y EPS CAGR	N/A	Target Price	$5.53
Consensus	Buy	Upside	+846.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMUX	$0.58	+1.78%	777.05K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMUX	$0.58	+1.8%	777.05K
3
4
5
6

IMUX

IMUX

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Immunic Inc. Data in Excel

Get Immunic Inc. Data in Excel